Monoclonal Antibody

Rituximab Fab </scene> in complex with an epitope peptide, 2osl" align="right"/>

Chimeric Antibodies

Different Types of Antibodies

One solution to this problem was the creation of chimeric antibodies. Chimeric anibodies are antibodies that have the , but have . These are created by fusing the Fab region coding DNA extracted from mice B-cells as above to human antibody DNA that only codes for the Fc region. Since it is the Fc region of an antibody that is glycosylated and used by the human immune system to determine self vs non-self, and the Fc region in chimeric antibodies is human, these chimeric antibodies typically cause a minimal immune response against them and thus have a longer half life. ^[5]. Chimeric antibodies typically have a “xi” before the “mab” at the end of their name to indicate their chain type, as is the case with “abciximab” (ReoPro), “cutximab” (Erbitux), or rituximab (Rituxan).

These chimeric antibodies can be further humanized through mutagenesis to the Fab sequence (excluding the ), identifying those parts which differ in humans and mutating them. This is a difficult process, but can create antibodies that are unrecognizable from human antibodies at the amino acid level. ^[6]. To avoid the added mutagenesis step, insertion of only the CDRs from mice into a full human antibody scaffold has been used to create humanized antibodies.^[7] Humanized antibodies typically have a “zu” before the “mab” to indicate their chain type. The drug Alemtuzumab (marketed by Genzyme for the treatment of leukemia) is an example of a humanized antibody with foreign CDR regions.

Human Antibody Production & Phage Display

The major drawback with chimeric antibody production is it still involves using rodents as the original source of antigen binding, and requires significant effort to identify, purify and create the fusion antibody. Applying a technique called phage display to monoclonal antibody production expedites this entire process. In phage display, DNA coding the binding region of the antibody is ligated into the genes of a phage which code for proteins that are expressed on the protein coat of the virus. This phage gene hybrid is then transformed into bacterial cells. The virus hijacks the bacterial replication machinery, producing vast quantities of phage. By using many different DNA fragments that are slightly different, a library of slightly different antibodies can be expressed on the outside of these phages, one type of antibody per phage. These antibody covered phages can then be selected for by running them through a column with the protein target immobilized on the column. Once the phages that bind the target protein well are identified, they can be used to reinfect bacterial cells and to isolate the DNA of antibodies that code for those antibodies with the greatest affinity for the target. Once the best antibodies are identified, they can be combined with human antibody scaffolds or human Fc regions as above to create humanized antibodies. ^{[8] [9]}Antibodies created through phage display have a “u” before the “mab” in their name to indicate their chain origins as is the case for Adalimumab ([ http://www.humira.com/ HUMIRA]) Template:STRUCTURE 1l6x

Glycosylation of Monoclonal Antibodies

Once an antibody gene is designed to contain the ideal sequence, the antibody then must be mass produced. An ideal system of production would be in bacterial cells because of the rapidity with which they replicate and ease of use. Unfortunately, bacterial cells do not glycosylate proteins the same way mammalian cells do. Since is critical for the immune system to recognize a protein as native, thus allowing the protein to stay in circulation in the human body without creating an immune response, antibody production had to be completed in cells that glycosylate the antibody appropriately. Chinese Hamster Ovary (CHO) cells are one type of cell that is able to glycosylate antibodies appropriately, but they are difficult to work with and relatively expensive at an industrial scale. Regardless, they are the most commonly used mammalian hosts for industrial production of recombinant protein therapeutics. ^[10] More recently, work by Dr. Tillman Gerngross, et al. have demonstrated that yeast can be genetically manipulated to produce human glycosylation on expressed antibodies. This is an important discovery because yeast replicate much faster than CHO cells, making them more ideal as hosts for industrial scale production of therapeutic proteins. ^[11] Gerngross’s startup company GlycoFi, which was based around this platform was purchased by Merck in 2006 and the technology is being employed in Merck’s pipeline. Gerngross’s new company, [www.adimab.com Adimab], also uses similar technology to produce human glycosylated proteins for the pharmaceutical industry.

Monoclonal Antibody Uses

Laboratory Research

Monoclonal antibodies have become a critical tool in most biochemistry labs. They are essential components in immunofluorescence experiments as well as in Western Blot and immuno dot blot tests to detect protein on a membrane.

Monoclonal Antibody Therapeutic Uses

Medical Applications

Monoclonal antibodies have been utilized to create four major classes of drugs. The first activate the bodies own immune system. An example of this is Rituximab (Marketed as Rituxan by Roche and Genentech). to CD20 surface proteins on B-Cells and illicits natural immune responses to these cancerous cells via ADCC, activating cellular apoptosis, or by attracting compliment proteins which kill the cell via the compliment pathway. ^[12] Another example of this type of monoclonal antibody drug is Infliximab (Marketed as [www.remicade.com/ Remicade] by Merck and the best selling Monoclonal therapeutic in 2008 with over $6 billion in sales). This class of antibodies also includes those antibodies that simply bind a target, disrupting a key mechanism in the diseased cells.

The second class of monoclonal antibody drugs are those conjugated to a disruptive compound. One example of this is used in Radioimmunotherapy (RIT). By conjugating a radioactive isotope to a murine antibody, targeted immunotherapy is possible. The antibody binds to the targeted cancer cell and the cell is damaged or destroyed by emitted beta particles. Murine antibodies are used because they are cleared from the body rapidly so as to avoid extensive radiation damage from the drug. This is the mechanism used by Tositumomab ([www.bexxar.com Bexxar]) which uses radioactive Iodine-131. ^[13] Also within this class of antibodies are those antibodies conjugated to a chemotherapy drug. An example of this type would be Gemtuzumab (marketed as Mylotarg by Wyeth until June 2010, when it was removed from the market due to inefficacy and safety concerns)

The Third class of monoclonal antibody drugs are those conjugated to a drug activating enzyme also known as Antibody-Directed Enzyme Prodrug Therapy (ADEPT). In this system, an enzyme that is able to activate a drug is attached to an antibody with specificity toward a target of choice. After injection of the antibody/enzyme compound and ample time for the antibodies to bind the target, a prodrug that is inert until activated by the enzyme is injected. This prodrug stays inert until it comes into contact with the antibody/enzyme compound bound to the target, whereupon the prodrug is activated and is able to attack cells in the local environment, which presumably would be populated by the infected target cells. No ADEPT system drugs have made it through the clinic yet, but the class holds promise. ^{[14] [15]}

The Final class of monoclonal antibody medical uses are those conjugated to liposomes or another form of nanotechnology drug delivery system. By attaching antibodies to the outside of a nanosized drug delivery device, large quantities of therapeutic drug can be delivered to a targeted environment. Many new nanotech devices including liposomes, nanotubes and other such containers have been developed and have demonstrated improved specificity for delivery existing drug compounds. ^[16]

Brand New Research

Here are some new tidbits of interesting information regarding monoclonal Antibodies

Lippow et al. have developed a computational method for improving antibody binding to targets. They were able to increase cetuximab (Erbitux) affinity 10 fold and comparable improvements in bevacizumab (Avastin), which disrupts Vascular Endothelial Growth Factor from binding VEGFR. ^[17]

Gribenko et al. developed a computation method for making any antibody more stable in the body by making specific changes to the amino acid sequence. ^[18]

A number of companies including MedImmune and Xencor have struck major deals in the past 2 years based on platforms of manipulating an antibodies Fc region to increase its half-life in the body or its immunological response. ^[19]

Additional 3D Structures of Selected Therapeutic Monoclonal Antibodies

1yy8,1yy9 – Crystal Structure of the Fab Fragment of Cetuximab (Erbitux)
3c08,3c09 – Crystal Structure of the Fab Fragment of Matuzumab (Discontinued by Takeda in 2008)
3gkw – Crystal Structure of the Fab Fragment of Nimotuzumab (anti-EGFR)
3giz – Crystal Structure of the Fab Fragment of Ofatumumab (anti-CD20, Arzerra)
3mlr, 3mls, 3mlt, 3mlu, 3mlv, 3mlw, 3mlx, 3mly, 3mlz – Crystal structure of anti-HIV V3 Fab in complex with various peptides
3hmw, 3hmx – Crystal Structure of Ustekinumab Fab 2osl – Crystal Structure of Rituximab Fab in complex with an epitope peptide
3iu3 – Crystal Structure of the Fab Fragment of Basiliximab in complex with CD25 ectodomain
3ixt – Crystal Structure of Motavixumab Fab bound to Peptide Epitope
3eo9, 3eoa, 3eob – Crystal Structure of Fab fragment of Efalizumab
1l6x – Fc Fragment of Rituximab bound to B Domain of Z34C

References

1. ↑ Roit, I. M. Roit's Essential Immunology. Oxford: Blackwell Science Ltd., 1997.
2. ↑ Roit, I. M. Roit's Essential Immunology. Oxford: Blackwell Science Ltd., 1997.
3. ↑ Ghosh AK, Spriggs AI, Taylor-Papadimitriou J, Mason DY. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies. J Clin Pathol. 1983 Oct;36(10):1154-64. PMID:6194183
4. ↑ Klee GG. Human anti-mouse antibodies. Arch Pathol Lab Med. 2000 Jun;124(6):921-3. PMID:10835540
5. ↑ Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1995 Nov;1(11):1311-8. PMID:9815926
6. ↑ Brady RL, Edwards DJ, Hubbard RE, Jiang JS, Lange G, Roberts SM, Todd RJ, Adair JR, Emtage JS, King DJ, et al.. Crystal structure of a chimeric Fab' fragment of an antibody binding tumour cells. J Mol Biol. 1992 Sep 5;227(1):253-64. PMID:1522589
7. ↑ Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323-7. PMID:3127726 doi:http://dx.doi.org/10.1038/332323a0
8. ↑ Barbas CF 3rd, Kang AS, Lerner RA, Benkovic SJ. Assembly of combinatorial antibody libraries on phage surfaces: the gene III site. Proc Natl Acad Sci U S A. 1991 Sep 15;88(18):7978-82. PMID:1896445
9. ↑ Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science. 1985 Jun 14;228(4705):1315-7. PMID:4001944
10. ↑ Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol. 2004 Nov;22(11):1393-8. PMID:15529164 doi:10.1038/nbt1026
11. ↑ Choi BK, Bobrowicz P, Davidson RC, Hamilton SR, Kung DH, Li H, Miele RG, Nett JH, Wildt S, Gerngross TU. Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris. Proc Natl Acad Sci U S A. 2003 Apr 29;100(9):5022-7. Epub 2003 Apr 17. PMID:12702754 doi:10.1073/pnas.0931263100
12. ↑ van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002 Sep 15;100(6):2257-9. PMID:12200395
13. ↑ Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007 Nov;48(11):1767-76. Epub 2007 Oct 17. PMID:17942813 doi:10.2967/jnumed.107.043489
14. ↑ Bagshawe KD. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Rev Anticancer Ther. 2006 Oct;6(10):1421-31. PMID:17069527 doi:10.1586/14737140.6.10.1421
15. ↑ Xu G, McLeod HL. Strategies for enzyme/prodrug cancer therapy. Clin Cancer Res. 2001 Nov;7(11):3314-24. PMID:11705842
16. ↑ http://www.nanotech-now.com/news.cgi?story_id=38872
17. ↑ Lippow SM, Wittrup KD, Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat Biotechnol. 2007 Oct;25(10):1171-6. Epub 2007 Sep 23. PMID:17891135 doi:10.1038/nbt1336
18. ↑ Gribenko AV, Patel MM, Liu J, McCallum SA, Wang C, Makhatadze GI. Rational stabilization of enzymes by computational redesign of surface charge-charge interactions. Proc Natl Acad Sci U S A. 2009 Feb 5. PMID:19196981
19. ↑ http://f1000scientist.com/article/display/57474/